{"id":32657,"date":"2024-12-30T15:00:00","date_gmt":"2024-12-30T15:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4586126_CN86126_0"},"modified":"2024-12-30T15:00:00","modified_gmt":"2024-12-30T15:00:00","slug":"bridge-biotherapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=32657","title":{"rendered":"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div id=\"dvContent\" readability=\"76.307501549907\">\n<p><span class=\"legendSpanClass\">SEONGNAM, <span class=\"xn-location\">South Korea<\/span> and <span class=\"xn-location\">BOSTON<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 30, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in&nbsp;South Korea&nbsp;developing novel drugs for fibrosis and cancer, today announced that&nbsp;James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on <span class=\"xn-chron\">Thursday, January 16, 2025<\/span>.<\/p>\n<p><b>Location:<\/b> Georgian Room (Mezzanine Level) at The Westin St. Francis<\/p>\n<p><b>Date: <\/b><span class=\"xn-chron\">Thursday, January 16, 2025<\/span><\/p>\n<p><b>Time:<\/b> <span class=\"xn-chron\">9:45-10:25 a.m. PST<\/span><\/p>\n<p><span id=\"spanHghlt4ff2\">During the conference, Bridg<\/span>e&nbsp;Biotherapeutics will also meet with potential partners and investors as the Company is looking for Business Development opportunities for further development of BBT-877, a novel drug candidate for idiopathic pulmonary fibrosis (IPF). Top-line results from the Phase 2 study of BBT-877 are expected in <span class=\"xn-chron\">April 2025<\/span>.<\/p>\n<p>To arrange a meeting with the Bridge Biotherapeutics team, send a meeting request <a href=\"https:\/\/www.bridgebiorx.com\/en\/m53.php#request\" target=\"_blank\" rel=\"nofollow noopener\">here<\/a>.<\/p>\n<p><b><span id=\"spanHghltd420\">About <\/span>Bridge Biotherapeutics, Inc.<\/b><\/p>\n<p>Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including fibrotic diseases and cancers. The company is developing BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-207, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more at <b><a href=\"https:\/\/www.bridgebiorx.com\/en\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.bridgebiorx.com\/en\/<\/a><\/b>.<\/p>\n<\/p><\/div>\n<p>Source: Bridge Biotherapeutics, Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 \/PRNewswire\/ &#8212; Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in&nbsp;South Korea&nbsp;developing novel drugs for fibrosis and cancer, today announced that&nbsp;James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025. Location: Georgian Room [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-32657","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=32657\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - My Blog\" \/>\n<meta property=\"og:description\" content=\"SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 \/PRNewswire\/ &#8212; Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in&nbsp;South Korea&nbsp;developing novel drugs for fibrosis and cancer, today announced that&nbsp;James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025. Location: Georgian Room [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=32657\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-30T15:00:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=32657#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=32657\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2024-12-30T15:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=32657\"},\"wordCount\":250,\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=32657\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=32657\",\"name\":\"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"datePublished\":\"2024-12-30T15:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=32657#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=32657\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=32657#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=32657","og_locale":"en_US","og_type":"article","og_title":"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - My Blog","og_description":"SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 \/PRNewswire\/ &#8212; Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in&nbsp;South Korea&nbsp;developing novel drugs for fibrosis and cancer, today announced that&nbsp;James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025. Location: Georgian Room [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=32657","og_site_name":"My Blog","article_published_time":"2024-12-30T15:00:00+00:00","author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=32657#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=32657"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference","datePublished":"2024-12-30T15:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=32657"},"wordCount":250,"articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=32657","url":"https:\/\/transmediavictoria.net.au\/?p=32657","name":"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"datePublished":"2024-12-30T15:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=32657#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=32657"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=32657#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/32657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32657"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/32657\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}